22,226 Shares in Progyny, Inc. (NASDAQ:PGNY) Acquired by Calamos Advisors LLC

Calamos Advisors LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNYGet Rating) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,226 shares of the company’s stock, valued at approximately $1,143,000.

Several other large investors also recently bought and sold shares of PGNY. American Century Companies Inc. grew its position in Progyny by 407.4% in the fourth quarter. American Century Companies Inc. now owns 2,323,001 shares of the company’s stock valued at $116,963,000 after acquiring an additional 1,865,151 shares in the last quarter. Riverbridge Partners LLC grew its position in Progyny by 87.7% in the first quarter. Riverbridge Partners LLC now owns 1,525,055 shares of the company’s stock valued at $78,388,000 after acquiring an additional 712,722 shares in the last quarter. Wafra Inc. grew its position in Progyny by 142.8% in the fourth quarter. Wafra Inc. now owns 763,018 shares of the company’s stock valued at $38,418,000 after acquiring an additional 448,820 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Progyny by 50.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,076,182 shares of the company’s stock valued at $54,186,000 after acquiring an additional 361,964 shares in the last quarter. Finally, Pictet Asset Management SA grew its position in Progyny by 50.2% in the fourth quarter. Pictet Asset Management SA now owns 557,159 shares of the company’s stock valued at $28,053,000 after acquiring an additional 186,195 shares in the last quarter. Institutional investors and hedge funds own 82.51% of the company’s stock.

Insider Transactions at Progyny

In other news, Director Norman Payson sold 6,618 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $32.09, for a total transaction of $212,371.62. Following the completion of the sale, the director now owns 477,592 shares of the company’s stock, valued at $15,325,927.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Chairman David J. Schlanger sold 1,452 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $31.21, for a total transaction of $45,316.92. Following the completion of the sale, the chairman now owns 82,548 shares of the company’s stock, valued at $2,576,323.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Norman Payson sold 6,618 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $32.09, for a total transaction of $212,371.62. Following the sale, the director now directly owns 477,592 shares of the company’s stock, valued at approximately $15,325,927.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,622 shares of company stock valued at $1,078,038. 14.00% of the stock is currently owned by corporate insiders.

Progyny Stock Down 1.0 %

Shares of NASDAQ:PGNY opened at $31.49 on Tuesday. Progyny, Inc. has a 52-week low of $25.67 and a 52-week high of $68.32. The company has a 50 day moving average of $30.67 and a two-hundred day moving average of $38.04. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of 56.23, a price-to-earnings-growth ratio of 8.17 and a beta of 1.96.

Progyny (NASDAQ:PGNYGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Progyny had a net margin of 10.09% and a return on equity of 23.15%. The company had revenue of $172.22 million during the quarter, compared to the consensus estimate of $167.49 million. On average, equities analysts anticipate that Progyny, Inc. will post 0.19 earnings per share for the current year.

Progyny Company Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Recommended Stories

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.